Published in J Exp Med on January 29, 2007
The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med (2009) 1.95
Self-reported symptoms of sleep disturbance and inflammation, coagulation, insulin resistance and psychosocial distress: evidence for gender disparity. Brain Behav Immun (2008) 1.87
mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev (2012) 1.74
Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun (2009) 1.66
PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta (2011) 1.60
The interleukin-17 receptor plays a gender-dependent role in host protection against Porphyromonas gingivalis-induced periodontal bone loss. Infect Immun (2008) 1.35
Sex differences in immune responses. Nat Rev Immunol (2016) 1.29
Peroxisome proliferator-activated receptor (PPAR)α and -γ regulate IFNγ and IL-17A production by human T cells in a sex-specific way. Proc Natl Acad Sci U S A (2012) 1.26
Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol (2012) 1.25
Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Immunol Rev (2012) 1.15
Regulation of Th17 differentiation by epidermal fatty acid-binding protein. J Immunol (2009) 1.11
Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease. J Immunol (2009) 1.03
The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells (2012) 1.00
Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J Exp Med (2010) 0.99
Sex-specific T-cell regulation of angiotensin II-dependent hypertension. Hypertension (2014) 0.98
Gender and sex hormones in multiple sclerosis pathology and therapy. Front Biosci (Landmark Ed) (2009) 0.95
No quiet surrender: molecular guardians in multiple sclerosis brain. J Clin Invest (2015) 0.90
PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis. PPAR Res (2008) 0.89
Targeting Nuclear Hormone Receptors: PPARα Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis. Int J Rheumatol (2011) 0.88
NKT cell subsets as key participants in liver physiology and pathology. Cell Mol Immunol (2016) 0.86
Sex and gender in psychoneuroimmunology research: past, present and future. Brain Behav Immun (2009) 0.84
Gng12 is a novel negative regulator of LPS-induced inflammation in the microglial cell line BV-2. Inflamm Res (2009) 0.83
The peroxisome-proliferator activated receptor-γ agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus. Clin Immunol (2013) 0.83
The role of nuclear receptors in regulation of Th17/Treg biology and its implications for diseases. Cell Mol Immunol (2015) 0.82
Protective role of gammadelta T cells in spontaneous ocular inflammation. Invest Ophthalmol Vis Sci (2009) 0.81
Regulation of Immune Responses and Autoimmune Encephalomyelitis by PPARs. PPAR Res (2010) 0.80
Disturbed subjective sleep in Chinese females with type 2 diabetes on insulin therapy. PLoS One (2013) 0.80
Resistance training and pioglitazone lead to improvements in muscle power during voluntary weight loss in older adults. J Gerontol A Biol Sci Med Sci (2013) 0.79
PPAR-alpha in cutaneous inflammation. Dermatoendocrinol (2011) 0.79
Androgens suppress antigen-specific T cell responses and IFN-γ production during intracranial LCMV infection. J Neuroimmunol (2010) 0.78
Sex differences and the role of PPAR alpha in experimental stroke. Metab Brain Dis (2015) 0.78
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α. J Biol Chem (2012) 0.78
Sex differences in the immune response to experimental stroke: Implications for translational research. J Neurosci Res (2017) 0.78
Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2016) 0.77
Gender-specific differences in PPARγ regulation of follicular helper T cell responses with estrogen. Sci Rep (2016) 0.77
αβ TCR⁺ T cells, but not B cells, promote autoimmune keratitis in b10 mice lacking γδ T cells. Invest Ophthalmol Vis Sci (2012) 0.76
New insights into androgenic immune regulation. Oncoimmunology (2014) 0.76
Cord blood leptin levels of healthy neonates are associated with IFN-γ production by cord blood T-cells. PLoS One (2012) 0.76
Candidate chromosome 1 disease susceptibility genes for Sjogren's syndrome xerostomia are narrowed by novel NOD.B10 congenic mice. Clin Immunol (2014) 0.76
A Journey in Science: The Privilege of Exploring the Brain and the Immune System. Mol Med (2016) 0.75
Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis. PPAR Res (2016) 0.75
Loss of PPARα perpetuates sex differences in stroke reflected by peripheral immune mechanisms. Metab Brain Dis (2016) 0.75
Sex-specific regulation of immune responses by PPARs. Exp Mol Med (2017) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 30.22
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
Multiple sclerosis. N Engl J Med (2000) 12.69
IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol (2006) 10.33
Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev (1999) 9.94
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med (2002) 8.33
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A (1997) 7.52
Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med (1978) 4.28
Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol (2002) 3.59
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem (1999) 3.57
Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell (1996) 3.48
A gender gap in autoimmunity. Science (1999) 3.33
Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology (1987) 3.11
Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med (1995) 2.75
Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med (1994) 2.70
A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice. J Clin Invest (1998) 2.42
Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest (2003) 1.87
Sex hormones in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neuroscientist (2001) 1.73
Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem (2004) 1.73
Age and sex associations of 40 autoimmune diseases. Am J Med (1994) 1.69
Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol (2004) 1.62
The distribution of serum immunoglobulins, anti-gamma-G globulins ("rheumatoid factors") and antinuclear antibodies in White and Negro subjects in Evans County, Georgia. Arthritis Rheum (1967) 1.57
It's all Rel-ative: NF-kappaB and CD28 costimulation of T-cell activation. Trends Immunol (2002) 1.52
Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum (1991) 1.50
Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. J Immunol (1999) 1.50
Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol (2002) 1.48
A yin-yang effect between sex chromosome complement and sex hormones on the immune response. Endocrinology (2005) 1.48
Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol (2002) 1.47
Role of TCR-induced extracellular signal-regulated kinase activation in the regulation of early IL-4 expression in naive CD4+ T cells. J Immunol (2003) 1.35
Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J Immunol (2001) 1.34
Sex differences in susceptibility to viral infection of the central nervous system. J Neuroimmunol (1996) 1.31
Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res (1996) 1.30
Androgens are protective in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neuroimmunol (2004) 1.30
Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol (1997) 1.29
Cutting edge: CD4+CD25+ regulatory T cells contribute to gender differences in susceptibility to experimental autoimmune encephalomyelitis. J Immunol (2005) 1.28
Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc Natl Acad Sci U S A (2003) 1.23
Androgen treatment prevents diabetes in nonobese diabetic mice. J Exp Med (1992) 1.13
The effect of peroxisome proliferators on microsomal, peroxisomal, and mitochondrial enzyme activities in the liver and kidney. Drug Metab Rev (1987) 1.09
Peroxisome proliferator-activated receptor alpha negatively regulates T-bet transcription through suppression of p38 mitogen-activated protein kinase activation. J Immunol (2003) 1.07
Gender influences herpes simplex virus type 1 infection in normal and gamma interferon-mutant mice. J Virol (2001) 1.02
Signaling by the JNK group of MAP kinases. c-jun N-terminal Kinase. J Clin Immunol (2001) 1.02
Weak TCR stimulation induces a calcium signal that triggers IL-4 synthesis, stronger TCR stimulation induces MAP kinases that control IFN-gamma production. Eur J Immunol (2001) 1.01
Sex difference in hepatic peroxisome proliferator-activated receptor alpha expression: influence of pituitary and gonadal hormones. Endocrinology (2003) 1.01
Gender-dependent IL-12 secretion by APC is regulated by IL-10. J Immunol (2000) 0.94
Sex differences in cytokine responses to myelin peptides in multiple sclerosis. J Neuroimmunol (2002) 0.92
Gender bias in Theiler's virus-induced demyelinating disease correlates with the level of antiviral immune responses. J Immunol (2005) 0.91
The neuroendocrine axis in patients with multiple sclerosis. Brain (1997) 0.89
Dysregulation of the hypothalamic-pituitary-gonadal axis in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroimmunol (2003) 0.86
Reprogramming transcription during the differentiation of precursor CD4+ T cells into effector Th1 and Th2 cells. Microbes Infect (1999) 0.85
Hepatic expression of PPARalpha, a molecular target of fibrates, is regulated during inflammation in a gender-specific manner. FEBS Lett (2003) 0.82
L-FABP is exclusively expressed in alveolar macrophages within the myeloid lineage: evidence for a PPARalpha-independent expression. Int J Biochem Cell Biol (2004) 0.81
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med (2002) 8.33
Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med (2007) 7.73
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med (2003) 6.73
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature (2002) 6.58
IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol (2008) 6.41
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 5.24
Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med (2004) 5.13
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med (2010) 4.78
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med (2002) 4.54
Induction and molecular signature of pathogenic TH17 cells. Nat Immunol (2012) 4.43
Thymic selection determines gammadelta T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma. Immunity (2008) 4.21
Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature (2007) 3.92
Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol (2009) 3.88
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature (2008) 3.48
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood (2007) 3.27
Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol (2006) 3.21
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet (2006) 3.13
Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med (2007) 3.09
Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev (2009) 2.96
CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol (2005) 2.83
The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet (2008) 2.83
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest (2006) 2.75
Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet (2003) 2.71
Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol (2006) 2.70
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med (2007) 2.64
Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther (2011) 2.61
Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat Neurosci (2011) 2.61
Design of effective immunotherapy for human autoimmunity. Nature (2005) 2.48
Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science (2005) 2.41
Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med (2012) 2.38
Myelin proteolipid protein-specific CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2004) 2.34
Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med (2002) 2.31
Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med (2005) 2.31
Extensive fusion of haematopoietic cells with Purkinje neurons in response to chronic inflammation. Nat Cell Biol (2008) 2.30
PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat Med (2009) 2.21
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood (2007) 2.19
Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci U S A (2010) 2.14
Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity (2011) 2.11
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest (2006) 2.10
Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A (2009) 2.07
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol (2013) 2.00
Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One (2009) 1.98
Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med (2007) 1.93
MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med (2013) 1.88
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol (2007) 1.86
Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J Clin Invest (2007) 1.78
Science Communication to the General Public: Why We Need to Teach Undergraduate and Graduate Students this Skill as Part of Their Formal Scientific Training. J Undergrad Neurosci Educ (2013) 1.76
The genetics of multiple sclerosis: an up-to-date review. Immunol Rev (2012) 1.74
Myelin regeneration: a recapitulation of development? Annu Rev Neurosci (2011) 1.70
Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med (2006) 1.69
Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clin Invest (2007) 1.67
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol (2011) 1.67
Innate and adaptive autoimmunity directed to the central nervous system. Neuron (2009) 1.66
Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol (2010) 1.66
Common variants in P2RY11 are associated with narcolepsy. Nat Genet (2010) 1.65
Tim-2 regulates T helper type 2 responses and autoimmunity. J Exp Med (2005) 1.63
Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation. Sci Transl Med (2013) 1.62
A writing-intensive course improves biology undergraduates' perception and confidence of their abilities to read scientific literature and communicate science. Adv Physiol Educ (2013) 1.61
What went wrong in the natalizumab trials? Lancet (2006) 1.60
Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol (2008) 1.59
TIM-4 expressed on APCs induces T cell expansion and survival. J Immunol (2008) 1.58
Chaperone activity of α B-crystallin is responsible for its incorrect assignment as an autoantigen in multiple sclerosis. J Immunol (2011) 1.56
Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet (2013) 1.55
Socioeconomic trends in hospitalization for multiple sclerosis. Neuroepidemiology (2010) 1.53
Aberrant mitochondrial fission in neurons induced by protein kinase C{delta} under oxidative stress conditions in vivo. Mol Biol Cell (2010) 1.49
Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion. Nat Med (2012) 1.48
Human aquaporin 4281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: relevance for diagnosing and monitoring patients with neuromyelitis optica. Arch Neurol (2012) 1.47
Iron deficiency accelerates Helicobacter pylori-induced carcinogenesis in rodents and humans. J Clin Invest (2012) 1.45
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest (2006) 1.43